Premium
Serum screening for Down syndrome and adverse pregnancy outcomes: a case‐controlled study
Author(s) -
Ogle Robert,
Jauniaux Eric,
Pahal Gurmit S.,
Dell Elissa,
Sheldrake Ann,
Rodeck Charles
Publication year - 2000
Publication title -
prenatal diagnosis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.956
H-Index - 97
eISSN - 1097-0223
pISSN - 0197-3851
DOI - 10.1002/(sici)1097-0223(200002)20:2<96::aid-pd766>3.0.co;2-#
Subject(s) - medicine , obstetrics , pregnancy , gestation , odds ratio , down syndrome , population , retrospective cohort study , incidence (geometry) , genetics , physics , environmental health , psychiatry , optics , biology
The relationship between adverse perinatal outcomes in women with false positive biochemical screening test for Down syndrome was investigated in a retrospective case‐controlled study. A cohort of 4000 women who booked for routine antenatal care and opted for biochemical screening over a 22 month period was obtained. The pregnancy outcome data of 272 women with a false positive screening test for Down syndrome (risk >1 in 250) at 15–18 weeks of gestation (study group) were compared with data from 272 age and gestation matched controls with a negative Down syndrome screening test from the same population. The frequency of normal and adverse perinatal outcomes, including pre‐eclampsia, isolated intrauterine growth restriction, spontaneous preterm labour and stillbirth was recorded. The incidence of adverse pregnancy outcomes was 11.9% in the study group and 8.6% in the control group. The estimated odds ratio of an abnormal outcome in the study group was 1.41 (95% CI—0.790, 2.55). The observed difference between proportion was 0.0324 (95% CI—0.022, 0.083; p =0.40). These data identify no evidence for a strong association between a false positive Down syndrome screening test result and subsequent adverse perinatal outcomes in the general population. Copyright © 2000 John Wiley & Sons, Ltd.